Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple SclerosisStephen L. Hauser, Ludwig Kappos, Amit Bar‐Or et al.|New England Journal of Medicine|2016Cited by 2k
Ocrelizumab versus Placebo in Primary Progressive Multiple SclerosisXavier Montalbán, Jerry S. Wolinsky, Stephen L. Hauser et al.|New England Journal of Medicine|2016Cited by 1.9k
Multiple sclerosisAlan J. Thompson, Olga Ciccarelli, Sergio E. Baranzini et al.|The Lancet|2018Cited by 1.8k
Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibilityNikolaos A. Patsopoulos, Efthimios Dardiotis, Sergio E. Baranzini et al.|Science|2019Cited by 1.4k
ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosisXavier Montalbán, Frauke Zipp, Ralf Gold et al.|Multiple Sclerosis Journal|2018Cited by 706